Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study

Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?

(2020) Liam Masterson et al.   INTERNATIONAL JOURNAL OF CANCER

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial

(2020) Jieqiong Liu et al.   Journal for ImmunoTherapy of Cancer

Properties of FDA-approved small molecule protein kinase inhibitors

(2019) Robert Roskoski   PHARMACOLOGICAL RESEARCH

A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer

(2019) Xiaofeng Chen et al.   ONCOLOGIST

VEGF in Signaling and Disease: Beyond Discovery and Development

(2019) Rajendra S. Apte et al.   CELL

Current status of immune checkpoint inhibition in early-stage NSCLC

(2019) J Vansteenkiste et al.   ANNALS OF ONCOLOGY

Immunotherapeutic approaches in nasopharyngeal carcinoma

(2019) James CH Chow et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The development of radiotherapy, image technology and chemotherapy prolongs the survival of patients with nasopharyngeal carcinoma: a cohort study with 20305 patients from 1990 to 2012

(2019) Xue-Song Sun et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials

(2019) Jia-Wei Lv et al.   Journal for ImmunoTherapy of Cancer

Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study

(2019) Yanjun Xu et al.   BRITISH JOURNAL OF CANCER

Radiogenomic analysis of vascular endothelial growth factor in patients with diffuse gliomas

(2019) Zhiyan Sun et al.   CANCER IMAGING

Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma

(2019) Jiawei Lv et al.   Nature Communications

Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study

(2018) Edwin P. Hui et al.   CLINICAL CANCER RESEARCH

Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study)

(2018) K.H. Au et al.   ORAL ONCOLOGY

Clinicopathologic and prognostic significance of VEGF, JAK2 and STAT3 in patients with nasopharyngeal carcinoma

(2018) Jin-Zhang Cheng et al.   Cancer Cell International

Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study

(2018) Chun-Yan Lan et al.   LANCET ONCOLOGY

A Meta-Analysis of Vascular Endothelial Growth Factor for Nasopharyngeal Cancer Prognosis

(2018) Feng Wang et al.   Frontiers in Oncology

Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response

(2016) P. Kickingereder et al.   CLINICAL CANCER RESEARCH

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

(2016) Jin Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

(2016) Li Zhang et al.   LANCET

Nasopharyngeal carcinoma

(2016) Melvin L K Chua et al.   LANCET

Ten years of anti-vascular endothelial growth factor therapy

(2016) Napoleone Ferrara et al.   NATURE REVIEWS DRUG DISCOVERY

Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation

(2011) E. P. Hui et al.   ANNALS OF ONCOLOGY

Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?

(2011) J.- C. Soria et al.   ANNALS OF ONCOLOGY

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

(2011) Shu Tian et al.   CANCER SCIENCE

A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma

(2011) Wan-Teck Lim et al.   CLINICAL CANCER RESEARCH

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial

(2011) Nancy Y Lee et al.   LANCET ONCOLOGY

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

(2010) Jin Li et al.   BMC CANCER

Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma

(2010) Edwin Pun Hui et al.   INVESTIGATIONAL NEW DRUGS

Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor†

(2008) Philip A. Harris et al.   JOURNAL OF MEDICINAL CHEMISTRY